AKEBIA THERAPEUTICS INC (AKBA)
Health Care · Kidney disease therapeutics · NASDAQ
A kidney-focused biopharmaceutical company commercializing oral treatments for anemia and iron management in dialysis patients, with mid-stage rare kidney disease assets.
What AKEBIA THERAPEUTICS INC does
Akebia Therapeutics is a fully integrated biopharmaceutical company focused on developing and commercializing innovative therapeutics for kidney disease. The company markets two commercial products: Vafseo® (vadadustat), an oral HIF-based treatment for anemia in dialysis patients launched in January 2025, and Auryxia® (ferric citrate), an oral medicine for serum phosphorus control and iron deficiency anemia in CKD patients. The company also maintains a pipeline of mid-stage and early-stage programs targeting rare kidney diseases and broader kidney-related indications.
Themes: ["Kidney disease / nephrology","Dialysis management","Chronic kidney disease (CKD)","Rare kidney diseases","HIF pathway / erythropoiesis","Complement inhibition"]
Fundamentals
- Price$1.43 as of 2026-07-09 close
- Market cap$381M as of 2026-07-10
- 1-year return-64.2% as of 2026-07-09 close
- Net margin-8.8% as of 2026-07-10
- Gross margin+79.3% as of 2026-07-10
- ROE-62.7% as of 2026-07-10
- Debt / equity7.09 as of 2026-07-10
- Revenue growth (YoY)+25.7% as of 2026-07-10
- Revenue CAGR (3y)-6.9% SEC XBRL
- Beta0.26 as of 2026-07-10
Key risks (from latest filing)
["Auryxia loss of exclusivity in March 2025 with generic competition from Teva and additional generics expected throughout 2026, creating significant revenue headwind for a historically meaningful product","Vafseo commercial uptake dependent on dialysis organization adoption and prescriber protocol implementation; currently only ~290,000 of estimated dialysis patients have prescribing access","Company is unprofitable with negative net margin of -8.83% and relies on continued commercial success of Vafseo and pipeline development to achieve profitability despite 25.69% revenue growth"]
Competitors & peers
- Amgen (AMGN)
- Fresenius Medical Care
- Teva Pharmaceuticals (TEVA)
- GSK (formerly ViiV Healthcare)
- FibroGen
- Dialysis organizations
- Dialysis patients
- CKD patients (dialysis-dependent and non-dialysis-dependent)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.